Company & Sponsor Intelligence
Luye Pharma Group Ltd.
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials5
Recruiting0
Completed5
Countries2
Therapeutic footprint
depressionparkinsons
Indexed studies
NCT04853407A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)
depression · ChinaPHASE3
depression · ChinaPHASE3
NCT03733561A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro
parkinsons · United StatesPHASE1
parkinsons · United StatesPHASE1
NCT03589066Pharmacokinetic Study of LY03003 in Patients With Parkinson's Disease
parkinsons · United StatesPHASE1
parkinsons · United StatesPHASE1
NCT02055274Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease
parkinsons · United StatesPHASE1
parkinsons · United StatesPHASE1
NCT04571164A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD
parkinsons · ChinaPHASE3
parkinsons · ChinaPHASE3
Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →